Global Intravenous (IV) Iron Drugs Market Report: 2016 Edition

  • ID: 3757818
  • Report
  • Region: Global
  • 51 Pages
  • Koncept Analytics
25 % OFF
until Dec 25th 2018
1 of 6
I.V. Iron Drugs: Increasing Cases of CKD and ERSD to Drive the Market

FEATURED COMPANIES

  • Allergan plc.
  • AMAG Pharmaceuticals
  • Galenica group
  • MORE
Iron is vital for multiple bodily functions, most importantly for the production of hemoglobin for red blood cells which are responsible for transporting oxygen in the blood. As an element, the only source of iron is from the diet. There is no way the body can produce iron itself. Intravenous (IV) treatment, in a broad sense, covers all the types of medications delivered intravenously, i.e. directly into the vein, through intravenous drip.

Compared to the other routes of infusing medications, the intravenous route is the fastest way to deliver fluids and medications throughout the body. The first iron product for intravenous use was high-molecular-weight iron dextran. Some of the major areas of IV iron application include gynecology, gastroenterology, oncology and surgeries. Hemoglobin, Ferritin, Transferrin, and Hepcidin are major molecules which are critical in the function and regulation of iron.

The key factors driving growth of the global I.V. iron industry include increase in number of dialysis cases, increasing global healthcare expenditures, rising ageing population, increasing life expectancy rate, growing number of ERSD patients and rising medicines expenditures. Some of the noteworthy trends and developments of this industry are new product development, introduction of the first generation drugs InFed (iron dextran) and Dexeferrum (iron dextra) and feraccru treatment penetration. However, the growth of this sector is being hindered by emerging anemia management therapies and associated risks.

The report analyzes the global iron products industry along with an extensive coverage of global, Europe and the US I.V. iron market. The global IV iron market witnesses intense competition with numerous top notch players; such as Galenica Pharmaceuticals, Actavis Inc, AMAG Pharmaceuticals; operating in the marketplace along with small budding players. As a part of analysis of fierce competition prevailing in the industry, product contention has been presented in the report. The company profiles of leading aforementioned players in the market are also incorporated in the report.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Allergan plc.
  • AMAG Pharmaceuticals
  • Galenica group
  • MORE
1. Iron in Human Body: An Introduction
1.1 I.V. Iron Application Areas
1.1.1 I.V. Iron Application in Nephrology
1.2 Iron Deficiency - Anemia
1.2.1 Iron Deficiency Metrics
1.3 I.V. Iron Therapies for Anemia Treatment
1.4 Types of I.V. Iron

2. Global Iron Product Market Analysis
2.1 Global Iron Product Market by Value
2.2 Global Iron Products Market Share by Segment

3. Global I.V. Iron Drugs Market Analysis
3.1 Global I.V. Iron Drugs Market by Value
3.2 Global I.V. Iron Drugs Market by Product
3.3 Global I.V. Iron Drugs Market Share by Product

4. I.V. Iron Drugs Regional Market Analysis
4.1 European I.V. Iron Drug Market
4.1.1 European I.V. Iron Drug Market by Value
4.1.2 European I.V. Iron Drug Market by Product
4.1.3 European I.V. Iron Drug Market Share by Product
4.2 The US I.V. Iron Drug Market
4.2.1 The US I.V. Iron Drug Market by Value
4.2.2 The US I.V. Iron Drug Market by Product
4.2.3 The US I.V. Iron Drug Market Share by Product
4.2.4 The US Non-dialysis I.V. Iron Drug Market by Volume
4.2.5 The US Non-dialysis I.V. Iron Drug Market Share by Product

5. Market Dynamics
5.1 Growth Drivers
5.1.1 Increase in Number of Dialysis Cases
5.1.2 Increasing Healthcare Expenditure
5.1.3 Increasing Cases of CKD and ESRD
5.1.4 Rising Ageing Population
5.1.5 Shift from Rural to Urban Regions
5.1.6 Prevalence of Iron Deficiency in Women
5.1.7 Increasing Life Expectancy Rate
5.1.8 Rising Medicines Expenditures
5.1.9 Growing Number of ERSD Patients
5.2 Trends
5.2.1 New Product Development
5.2.2 Introduction of First Generation Drugs InFeD and Dexeferrum
5.2.3 Feraccru Treatment Penetration
5.3 Challenges
5.3.1 Emerging Anemia Management Therapies
5.3.2 Potential Risks of I.V. Iron

6. Competitive Landscape
6.1 Product Comparison

7. Company Profiles
7.1 Galenica group
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategies
7.2 AMAG Pharmaceuticals
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategies
7.3 Allergan plc.
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategies

8. Market Outlook
8.1 Market Forecast
8.2 Forecast Methodology
8.2.1 Dependent and Independent Variables
8.2.2 Correlation Analysis
8.2.3 Regression Analysis

List of Charts

- Global Iron Product Market by Value (2011-2015)
- Global Iron Products Market Share by Segment (2015)
- Global I.V. Iron Drugs Market by Value (2010-2015)
- Global I.V. Iron Drugs Market by Product (2010-2015)
- Global I.V. Iron Drugs Market Share by Product (2015)
- European I.V. Iron Drug Market by Value (2010-2015)
- European I.V. Iron Drug Market by Product (2010-2015)
- European I.V. Iron Drug Market Share by Product (2015)
- The US I.V. Iron Drug Market by Value (2010-2015)
- The US I.V. Iron Drug Market by Product (2010-2015)
- The US I.V. Iron Drug Market Share by Product (2015)
- The US Non-dialysis I.V. Iron Drug Market Volume (2010-2015)
- The US Non-dialysis I.V. Iron Drug Market Share by Product (2015)
- Global Dialysis Patient Population (2007-2015E)
- Global Dialysis Patients by Type (2014)
- Global Health Care Expenditure Per Capita (2007-2015E)
- The US Healthcare Expenditure Per Capita (2007-2015E)
- Global Ageing Population (2006-2015E)
- Global Urban Population (2007-2015E)
- Prevalence of Iron Deficiency in Women in the US
- The US Female Population (2007-2015E)
- Global Life Expectancy Rate (2007-2015E)
- Global Spending on Medicines (2010-2020E)
- The US Spending on Medicine (2007-2015)
- Global ERSD Patients (2009-2020E)
- Global Addressable Patients for Feraccru by Underlying Disease - Developed World
- Galenica’s Net Sales Share by Business Segments (2015)
- Galenica’s Net Sales Share by Region (2015)
- Galenica’s Net Sales and Net Profit (2011-2015)
- AMAG Pharmaceuticals’ Revenue and Net Income (2011-2015)
- Allergan Plc.’s Net Sales Business Segment (2015)
- Allergan Plc.’s Revenue and Net Income (2011-2015)
- Global I.V. Iron Drug Market Forecast (2014-2019E)

List of Tables

- Risk Factors for CKD
- Emerging Non-Intravenous Therapies for Anemia Management
- Comparison between Injectafer® and Venofer®
- Summary of Feraccru vs. IV Iron Profile
- Dependent & Independent Variables (2011-2015)
- Correlation Matrix
- Model Summary - Coefficient of Determination
- Regression Coefficients Output
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Allergan plc.
  • AMAG Pharmaceuticals
  • Galenica group
  • MORE
The global I.V. iron drugs market is growing rapidly due to improvement in the quality of treatment outside dialysis, increasing number of dialysis patients, growing number of ERSD patients worldwide and growing ageing population. Moreover, increasing cases of hypertension, rising healthcare expenditure, prevalence of iron deficiency in women, large potential in new therapeutic areas and higher spending on medicine are also supporting the growth of I.V. iron drugs market.

The US and Europe represents key regions for the I.V. iron market. The US is has been steadily increasing over the past couple of years as fueling the spending power of individuals on healthcare and accelerating economic growth.

As per the report "Global I.V. Iron Market: 2016 Edition", the demand for I.V. iron drugs will be driven by increasing number of dialysis cases, increasing healthcare expenditure, increasing cases of CKD and ERSD, rising ageing population, shift from urban to rural region, prevalence of iron deficiency in women, increasing life expectancy rate, rising medicine expenditure and growing number of ERSD patients.

Some of the noteworthy trends and development in I.V. iron drugs market are new product development, introduction of the first generation drugs InFed (iron dextran) and Dexeferrum (iron dextra) and feraccru treatment penetration. However, the growth of this sector is being hindered by emerging anemia management therapies and associated risks.

The report presents an exhaustive study of global, Europe and the US I.V. iron market. A thorough analysis has been conducted on key market players covering their business overview, product portfolio, financial overview and business strategies.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
Note: Product cover images may vary from those shown
5 of 6
- AMAG Pharmaceuticals
- Allergan plc.
- Galenica group
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll